Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
| ▸ | GABRE | P78334 | 2/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18704808 | 0.88 | KDM4E (0.50) | KDM4EKMT2AMEN1TDP1GLA | |
| SCHEMBL2806672 | 0.85 | KDM4E (0.59) | KDM4EKMT2AMEN1TDP1GLA | |
| SCHEMBL762108 | 0.84 | KDM4E (0.50) | KDM4EKMT2AMEN1TDP1GLA | |
| SCHEMBL13917234 | 0.84 | KDM4E (0.50) | KDM4EKMT2AMEN1TDP1GLA | |
| SCHEMBL2808091 | 0.83 | KDM4E (0.57) | KDM4EKMT2AMEN1TDP1GLA | |
| SCHEMBL1291691 | 0.82 | KDM4E (0.48) | KDM4EKMT2AMEN1TDP1GLA | |
| SCHEMBL20142067 | 0.81 | GAA (0.55) | KDM4EKMT2AMEN1TDP1LCK | |
| SCHEMBL9273458 | 0.81 | KDM4E (0.47) | KDM4EKMT2AMEN1TDP1GLA | |
| SCHEMBL27720321 | 0.80 | KDM4E (0.66) | KDM4EKMT2AMEN1TDP1GLA | |
| SCHEMBL20541572 | 0.79 | KDM4E (0.46) | KDM4EKMT2AMEN1TDP1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2025-05-29 | — | — | US | disclosed |
| EP-2836216-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. (US) | 2015-02-18 | — | — | EP | disclosed |
| WO-2013155464-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. (US) | 2013-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | KDM4E 753/4885KMT2A 803/4885MEN1 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.